Mark Barr, MD
Family Medicine · Richmond, VANPI 1962473371
Payments from drug & device makers
Across 188 payments — averaging $14.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$604
- Novo Nordisk$486
- AstraZeneca$298
- Lilly USA, LLC$269
- Amgen$245
- Bayer$152
- plus $705 from 22 others
What the payments were for
- Food & beverage$2,760100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 42 | $604 |
| Novo Nordisk | 36 | $486 |
| AstraZeneca(2 entities) | 19 | $298 |
| Lilly USA, LLC | 12 | $269 |
| Amgen | 18 | $245 |
| Bayer | 13 | $152 |
| Boehringer Ingelheim | 8 | $128 |
| Sanofi-aventis U.S. LLC | 5 | $79 |
| Pfizer | 5 | $79 |
| Merck | 4 | $57 |
| GSK | 3 | $47 |
| Johnson & Johnson | 3 | $36 |
| Inspire Medical Systems, Inc. | 2 | $34 |
| Novartis | 2 | $27 |
| Mylan Specialty L.p. | 2 | $25 |
| Biohaven Pharmaceuticals, Inc. | 2 | $24 |
| Impulse Dynamics (USA) Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $17 |
| Abbott | 1 | $16 |
| Edwards Lifesciences | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Grifols USA, LLC | 1 | $12 |
| Eisai Inc. | 1 | $12 |
| Genentech USA, Inc. | 1 | $12 |
| Clarus Therapeutics Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$118
How this compares
$2,760 in reported general payments places this provider in the 80th percentile of 2,553 family medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 60 | $81,222 |
| EliquisApixaban | 57 | $58,409 |
| TrulicityDulaglutide | 22 | $37,628 |
| XareltoRivaroxaban | 41 | $32,244 |
| FarxigaDapagliflozin Propanediol | 21 | $25,501 |
| RybelsusSemaglutide | 13 | $22,762 |
| JardianceEmpagliflozin | 17 | $22,174 |
| Rosuvastatin Calcium | 630 | $8,951 |
| Testosterone | 16 | $8,271 |
| Atorvastatin Calcium | 506 | $3,937 |
| Tramadol Hcl | 180 | $2,776 |
| Colchicine | 22 | $2,649 |
| Levothyroxine Sodium | 253 | $2,390 |
| Esomeprazole Magnesium | 39 | $2,233 |
| Losartan Potassium | 217 | $2,229 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $486 | $103,98373 claims |
| PfizerEliquis | $79 | $58,40957 claims |
| Lilly USA, LLCTrulicity | $269 | $37,62822 claims |
| Johnson & JohnsonXarelto | $36 | $32,24441 claims |
| AstraZenecaFarxiga | $298 | $25,50121 claims |
| Boehringer IngelheimJardiance | $128 | $22,17417 claims |
| AbbVieSynthroid | $604 | $1,79551 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in Richmond
- Paul StairsRichmond$105K
- Edwin RobinsonRichmond$83K
- Banks TurnerRichmond$74K
- James FosterRichmond$27K
- George MaughanRichmond$21K
- Aaron HartmanMidlothian$17.4M
- John ScottGlen Allen$16.7M
- Banu MyneniPortsmouth$12.8M
- Patricia HouserWinchester$3.5M
- Stephan JannachDanville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.